Erin Lavelle

Erin Lavelle is an accomplished biopharma executive with over 25 years of strategic and operational leadership experience in the biopharmaceutical industry. Most recently as the chief operating officer and chief financial officer of ProfoundBio, Ms. Lavelle led the company’s $1.8 billion acquisition by Genmab and the $112 million oversubscribed Series B financing preceding the acquisition, and spearheaded the company’s public company readiness efforts. Before joining ProfoundBio, Ms. Lavelle served as chief operating officer and chief financial officer at Eliem Therapeutics, where she executed a combined $150 million Series B financing and initial public offering. Prior to Eliem, Ms. Lavelle was the chief operating officer at Alder BioPharmaceuticals, where she led the company’s $2.3 billion acquisition by H. Lundbeck A/S. Prior to Alder, she held a variety of roles of increasing responsibility during 15 years at Amgen and was a healthcare investment banker at Merrill Lynch & Co. She received her BA in Economics from Yale University.